Corvus Pharmaceuticals experienced a 31.1% increase in short interest in September.
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) saw a 31.1% rise in short interest in September, totaling 2,150,000 shares. The company reported a net loss of $0.07 per share, better than expected. It holds a market cap of $420.34 million and a PE ratio of -12.92. Analysts have mixed ratings, with one downgrading it to "sell" while others raised price targets, averaging $10.83. Institutional investors own 46.64% of the company.
October 15, 2024
4 Articles